Gastrointestinal in Biological Technology

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

... or orBec((R))) for the treatment of gastrointestinal symptoms associated with chronic ... side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism ... BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. ...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

... inactivation of peptides by enzymes in the upper gastrointestinal tract. Other sensitive drugs that can be ... side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism ... BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. ...

New Report Just Published: World Endoscopy Systems Market Report

... Major Areas of Endoscopy Application II-23 gastrointestinal II-23 Capsule Endoscopy II-24 Upper ... Endoscopic System II-40 Olympus Introduces gastrointestinal Endoscopy System II-41 KARL STORZ Introduces ... System II-42 Olympus Launches Two Innovative gastrointestinal Video-Scopes II-42 Solos Endoscopy Launches ...

Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome

... , the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome . ... Elevated levels of serotonin contribute to the gastrointestinal and possibly other symptoms experienced by these ... designed to evaluate LX1032's effect on the gastrointestinal symptoms experienced by patients with carcinoid ...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

... non-infectious inflammation of the lung in acute gastrointestinal Graft-versus-Host disease (GI GVHD) patients who ... dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 109: 4557 - ... locally acting therapy tailored to treat the gastrointestinal manifestation of GVHD, the organ system where ...

Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy

... muscle function and strength, cognitive function, gastrointestinal function, pain, quality of life, insulin ... significant impairments in cognitive function, gastrointestinal function or pain, Insmed was unable to reach any ... cataracts, as well as well as endocrine, sexual, gastrointestinal and reproductive disturbances. There is ...

AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated With NSAID Use

... , a program to increase awareness about the gastrointestinal (GI) risks associated with the use of ... who research, diagnose and treat disorders of the gastrointestinal tract and liver. The AGA administers all ... of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. For more information, please visit ....

Boston Scientific's SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)

... of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American ... (AGA) Institute, the American Society for gastrointestinal Endoscopy and the Society for Surgery of the ... hundreds of lectures on the latest advances in gastrointestinal research, medicine and technology. For more ...

Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology

... Renal Cell Carcinoma, Colorectal Cancer and gastrointestinal Stromal Tumors (GIST) NEW YORK, May 18 ... 8:00am - 12:00pm (Level 2, West Hall C) gastrointestinal Stromal Tumor (GIST) Sunday, May 31 ... imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). Lead Author: Anthony ...

DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments

... trial of orBec(R) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD). ... side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism ... BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. ...

DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments

... side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism ... BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. ... which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's ...

Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome

... abnormality and symptoms often overlap with other gastrointestinal conditions, such as inflammatory bowel disease, ... by determining the patient does not have other gastrointestinal diseases with similar symptoms, together with the ... on the detection, diagnosis and treatment of gastrointestinal diseases and disorders in the United States. Its ...

DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors

... side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism ... BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. ... which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's ...

DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer

... side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism ... BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. ... which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's ...

Cancer Advances Acquires the Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers

... the immune system for application in three gastrointestinal cancers. Cancer Advances was created as a wholly ... compounds in the development and progression of gastrointestinal tumors. Prior to the acquisition of this ... targeting a $1 billion market. In the US, gastrointestinal cancer has the second highest incidence, ...

ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development

... Chemokine Receptor CCR9 for gastrointestinal Diseases MOUNTAIN VIEW, Calif., Oct. 15 ... in the CCR9 arena and expands the company's gastrointestinal franchise with the potential to pursue different ... colitis and other inflammatory disorders of the gastrointestinal system. This chemokine receptor is known to play ...

Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery

... nausea, diarrhea and swelling (edema)(3). About gastrointestinal stromal tumors (GIST) gastrointestinal stromal tumors (GIST) belong to a group of ... Cancer Reference Information. Detailed Guide for gastrointestinal Stromal Tumors. Key Statistics. ...

AMDL ELISA DR-70(R) (FDP) is Promising as Effective Cancer Detection Test

... DR-70 ELISA (FDP) test as a detection test for gastrointestinal cancers that include, colorectal, esophageal, ... to be significantly higher across all types of gastrointestinal cancers tested and not limited to specific tumor ... differs between patients with cancer of the gastrointestinal tract or the hepatobilary system and healthy ...

AMITIZA(R) (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women

... in patients with known or suspected mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the ... older, and is developing the drug for additional gastrointestinal disorders with large potential markets. In ...

Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation

... Conference is to bring together scientists in the gastrointestinal field to discuss important scientific issues ... to foster discussion, engage and update gastrointestinal professionals on new and emerging technologies, ... we are able to better contribute to the gastrointestinal practice and bring forth new ideas and ...

Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening

... might indicate colorectal cancer or other lower gastrointestinal diseases. FIT tests help identify individuals ... screening aid for detecting primarily lower gastrointestinal bleeding disorders that may be related to iron ... adenomas, colorectal cancers or other gastrointestinal lesions that can bleed. Health professionals ...

Cure HIV Reaches Out to Foundation Community to Fund LiSAVIOR

... do not treat the growth of HIV in the gastrointestinal tract. HIV virus multiplies and mutates in the gastrointestinal tract and then is reabsorbed into the blood. This ... needles or during sexual intercourse. The gastrointestinal tract is comprised of the mouth and ...

Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO

... bearing the RAAG12 antigen, particularly those of gastrointestinal (GI) origin, was conducted at 5 institutions in ... surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, and ... is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery ...

M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer

... Dr. Harris has extensive experience in gastrointestinal diseases as well as clinical and regulatory ... to conduct exploratory trials for multiple gastrointestinal indications including Pouchitis, an orphan ... proprietary compounds to treat a broad range of gastrointestinal and liver diseases. Based in San Diego, Ocera was ...

Prometheus Licenses COLAL-PRED(R) From Alizyme

... to develop and commercialize COLAL-PRED(R) for gastrointestinal diseases or other applications in North America ... of therapeutics and complementary diagnostics to gastrointestinal specialists throughout the United States, we ... pharmaceutical products, thus strengthening our gastrointestinal franchise for the future. COLAL-PRED can provide ...

FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML

... (0%, 1%), and hemorrhage (10%, 14%) including gastrointestinal bleeding (1%, 4%). In this same study, the ... nausea (24%, 33%); hemorrhage (18%, 8%) including gastrointestinal bleeding (3%, 0%), and vomiting (10%, 24%). In ... (3%), infection (2%), febrile neutropenia (4%), gastrointestinal bleeding (4%), dyspnea (3%), sepsis (1%), ...

Recent Study Confirms Alimentary Health's Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome

... of safe and effective therapeutics for gastrointestinal (GI) and other indications. Bifantis has been ... probiotic and pharmabiotic treatments for gastrointestinal disorders and other inflammatory conditions. ... It does this by helping establish a healthy gastrointestinal flora. Align is the only probiotic supplement ...

Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis

... of proprietary compounds to treat gastrointestinal and liver diseases announced today that data from ... proprietary compounds to treat a broad range of gastrointestinal and liver diseases. Ocera Therapeutics is based ... of AST-120 in Crohn's disease and other gastrointestinal and liver diseases including Pouchitis, Hepatic ...

FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

... feature of IBS-C. The hypersensitivity of the gastrointestinal system of individuals with IBS-C makes them more ... should not be used in patients with a known gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be evaluated to confirm the ...

Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration

... (IBS-C), chronic constipation (CC), and other gastrointestinal disorders. (Logo: ... tested for the treatment of IBS-C, CC, and other gastrointestinal disorders. Linaclotide is an agonist of guanylate ... for the treatment of IBS-C, CC, and other gastrointestinal disorders; and MD-0727 and MD-3124 for the ...

Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting

... of NKTR-118 reverse the effects of morphine on gastrointestinal transit time at doses that do not reverse a ... The trial measured the morphine-induced delay in gastrointestinal transit time, a peripheral effect, using the lactulose hydrogen gastrointestinal motility test. Pupillometry, a measurement of the ...

NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region

... in recent decades, as it has revolutionized the approach to many upper gastrointestinal disorders. Helicobacter pylori is believed to cause a spectrum of ... company that develops and markets a wide range of products to treat gastrointestinal diseases and disorders, such as inflammatory bowel disease, cholestatic ...

Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration

... The conversion of Vyvanse to d -amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times. ... and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the ...

Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment

... The conversion of VYVANSE to d -amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times. ... and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the ...

Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients

... reported in the study and was associated with the presence of iron in the gastrointestinal tract. With the exception of the reporting of darkened stool as an (asymptomatic) adverse event, the gastrointestinal adverse event profile was similar in incidence to that reported for other ...

FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD

... The conversion of VYVANSE to d -amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times. ... deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the ...

Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients

... events (SAEs) was seven percent and the most frequent SAEs involved gastrointestinal disorders (five percent) and infections and infestations (2 percent). ... chronic, progressive, destructive disorder that causes inflammation of the gastrointestinal (GI) tract, most commonly at the end of the small intestine (the ileum) ...

Zeus to Present at Digestive Disease Week in Chicago

... new and innovative medical devices for interventional procedures in gastrointestinal endoscopy and Natural Orifice Translumenal Endoscopic Surgery (NOTES). ... and other professionals in the fields of gastroenterology, endoscopy, gastrointestinal surgery, and hepatology. When Dr. Naomi Nakao, a prolific inventor ...

Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week

... syndrome (IBS), and LX1032 , an oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome . The presentations will ... researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. LX1031 is currently in a Phase 2 clinical trial in patients with ...

China-Biotics, Inc. to Attend Digestive Disease Week 2009

... Week (DDW) is the largest and most prestigious meeting in the world for gastrointestinal professionals in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Every year, it attracts approximately 16,000 physicians, ...